Scientists from the University of Pittsburgh, in collaboration with the University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, have shed light on how the long noncoding RNA (lncRNA) EPIC1 plays a crucial role in conferring resistance to immunotherapies in tumors. Their research revealed that EPIC1 inhibits the accumulation of cytoplasmic double-stranded RNA (dsRNA), suppresses type I interferon (IFN) responses, and hampers antitumor immunity within tumor cells. Studies conducted both in vitro and in vivo demonstrated that targeting EPIC1 RNA in cells and mouse models of cancer could enhance the effectiveness of checkpoint blockade therapies and slow down tumor growth. Specifically, silencing EPIC1 was found to enhance the therapeutic impact of the PD-1 Inhibitor pembrolizumab in a humanized mouse model of triple negative breast cancer (TNBC).
The lead author, Dhamotharan Pattarayan, PhD, from the University of Pittsburgh Center for Pharmacogenetics, detailed these findings in their published paper in Science Signaling, where they labeled EPIC1 as a critical regulator of dsRNA-mediated type I IFN responses. The team’s conclusion highlighted EPIC1 as a promising therapeutic target to improve the efficacy of immunotherapy treatments, especially in addressing resistance mechanisms encountered in cancers like TNBC. Despite the progress made in immunotherapies such as PD-1 blockade, challenges persist in their widespread success, with issues like patient eligibility, treatment responsiveness, and tumor resistance posing significant hurdles. Identifying biomarkers and targets that can predict and overcome immunotherapy resistance remains a pressing need in the clinical management of cancer patients undergoing such treatments.
Through their study, Pattarayan and colleagues pinpointed EPIC1 as a noteworthy target due to its involvement in promoting tumor evasion mechanisms. Their research emphasized the pivotal role of noncoding RNAs, particularly lncRNAs, in regulating cancer epigenetics. They highlighted EPIC1’s interaction with key regulators like EZH2 and MYC to facilitate tumorigenesis and immune evasion in cancer cells. By revealing EPIC1’s role in inhibiting type I interferon signaling and dsRNA accumulation, the team proposed that targeting this lncRNA could reverse these immunosuppressive effects, thereby reactivating antitumor immune responses. Moreover, the study demonstrated that depleting EPIC1 levels through oligonucleotide targeting led to reduced tumor growth in triple-negative breast cancer models in mice, accompanied by increased immune cell infiltration into tumors.
The findings further underscored the potential of EPIC1 as a predictive biomarker for immunotherapy resistance across various cancers and its utility as a therapeutic target to enhance treatment outcomes. By enhancing dsRNA accumulation within tumors, knocking down EPIC1 was shown to sensitize tumor-bearing mice to PD-1 inhibitor treatment, suggesting a synergistic effect when combining EPIC1 targeting with immunotherapy strategies. This research illuminates a promising avenue for developing combination therapies that leverage EPIC1 inhibition to augment the efficacy of immunotherapies in combatting treatment-resistant cancers, offering hope for improved patient outcomes.
Key Takeaways:
– EPIC1, a long noncoding RNA, plays a significant role in promoting tumor resistance to immunotherapies by suppressing antitumor immune responses.
– Targeting EPIC1 has shown promise in enhancing the efficacy of checkpoint blockade therapies, particularly in triple negative breast cancer.
– Depleting EPIC1 levels can sensitize tumors to PD-1 inhibitor treatment, demonstrating its potential as a therapeutic target to overcome immunotherapy resistance.
– EPIC1 inhibition presents a viable strategy to reinvigorate antitumor immunity and improve treatment outcomes in cancers where immunotherapy faces challenges.
Tags: immunotherapy, biotech
Read more on genengnews.com